Pharmaceutical composition comprises 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. a. rosiglitazone in the form of a free base or a tautomeric form thereof and/or in the form of a pharmaceutically acceptable derivative and a sulphonylurea preferably glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. Also disclosed is the use of 2 to 8 mg of rosiglitazone and a sulphonylurea for the manufacture of a medicament for the treatment of diabetes mellitus and/or conditions associated with diabetes mellitus the use of 2 to 8 mg of rosiglitazone for the manufacture of a medicament for administration together with a sulphonylurea for the treatment of diabetes mellitus and/or conditions associated with diabetes mellitus and the use of a sulphonylurea for the manufacture of a medicament for administration together with 2 to 8 mg of rosiglitazone for the treatment of diabetes mellitus and/or conditions associated with diabetes mellitus.

暂无附图